Karyopharm Therapeutics | KPTI - Equity Capital And Reserves


Karyopharm Therapeutics reported $-292.93M in Equity Capital and Reserves for its fiscal quarter ending in December of 2025.





Equity Capital And Reserves Change Date
AbbVie USD -3.27B 628M Dec/2025
Abbott USD 52.13B 1.3B Dec/2025
Amgen USD 8.66B 961M Dec/2025
AstraZeneca USD 48.67B 2.78B Dec/2025
BioCryst Pharmaceuticals USD -119.15M 268.74M Dec/2025
Bristol-Myers Squibb USD 18.55B 1.06B Sep/2025
Eli Lilly USD 26.54B 2.74B Dec/2025
Enanta Pharmaceuticals USD 126.59M 61.87M Dec/2025
GlaxoSmithKline GBP 16.38B 229M Dec/2025
Incyte USD 5.17B 516.28M Dec/2025
J&J USD 81.54B 3.07B Dec/2025
Karyopharm Therapeutics USD -292.93M 23.67M Dec/2025
MacroGenics USD 55.59M 11.41M Dec/2025
Merck USD 51.85B 2.79B Sep/2025
Nektar Therapeutics USD 89.83M 4.75M Dec/2025
Novartis USD 46.13B 1.38B Dec/2025
Novartis USD 46.13B 1.8B Dec/2025
Pfizer USD 92.8B 4.11B Sep/2025
Regeneron Pharmaceuticals USD 31.26B 299.1M Dec/2025
Roche Holding CHF 33.8B 758M Dec/2025
Sangamo BioSciences USD 19.6M 14.7M Jun/2025
Takeda JPY 7.64T 513.39B Dec/2025
Tectonic Therapeutic USD 251.33M 16.2M Dec/2025
TG Therapeutics USD 648.02M 40.8M Dec/2025
Ultragenyx Pharmaceutical USD 9.16M 142.13M Sep/2025
Xencor USD 635.59M 10.27M Dec/2025